Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gw-274150. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 known ✓ | P35228 | 3/20 | 0.54 |
| ▸ | BHMT | Q93088 | 11/20 | 0.54 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.54 |
| ▸ | NOS3 | P29474 | 2/20 | 0.54 |
| ▸ | NOS1 | P29475 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gw-274150 SCHEMBL1690580 | 1.00 | BHMT (0.54) | BHMTBHMT2NOS2NOS3NOS1 | |
| Gw-274150 SCHEMBL120694 | 1.00 | BHMT (0.54) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL28352319 | 0.87 | TSHR (0.62) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL28352320 | 0.87 | TSHR (0.62) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL8470091 | 0.85 | ARG1 (0.53) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL5511756 | 0.85 | ARG1 (0.53) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL2757814 | 0.85 | ARG1 (0.53) | BHMTBHMT2NOS2NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL5514291 | 0.84 | ARG1 (0.51) | BHMTBHMT2NOS2NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL5514288 | 0.84 | ARG1 (0.51) | BHMTBHMT2NOS2NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL8469599 | 0.84 | ARG1 (0.51) | BHMTBHMT2NOS2NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1089 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | claimed |
| US-20250276085-A1 | SYNTHETIC MULTIDOMAIN PEPTIDE BIOMATERIALS THAT INHIBIT INDUCIBLE NITRIC OXIDE SYNTHASE | WILLIAM MARSH RICE UNIVERSITY (US) | 2025-09-04 | — | — | US | claimed |
| US-12163161-B2 | In vitro method for identifying thoracic aortic aneurysms (TAA) in a subject | CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III (F.S.P.) (ES) | 2024-12-10 | — | — | US | claimed |
| WO-2024231899-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-11-14 | — | — | WO | claimed |
| EP-3427061-B1 | USE OF SELECTIVE INOS INHIBITORS FOR TREATING THORACIC AORTIC ANEURYSM | CENTRO NAC DE INVESTIGACIONES CARDIOVASCULARES CARLOS III F S P (ES) | 2023-12-06 | — | — | EP | claimed |
| WO-2022219196-A1 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND/OR TREATMENT OF THORACIC AORTIC ANEURYSM | CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III (F.S.P.) (ES) | 2022-10-20 | — | — | WO | claimed |
| US-20210060123-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | LEVICEPT LTD (GB) | 2021-03-04 | — | — | US | claimed |
| US-20210009549-A1 | CANNABINOID DERIVATIVES AND CONJUGATES AND USES THEREOF | BEETLEBUNG PHARMA LTD (IL) | 2021-01-14 | — | — | US | claimed |
| US-20180161392-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | LEVICEPT LTD (GB) | 2018-06-14 | — | — | US | claimed |
| EP-2825208-B1 | P75NTR NEUROTROPHIN BINDING PROTEIN FOR THERAPEUTIC USE | LEVICEPT LTD (GB) | 2017-05-17 | — | — | EP | claimed |
| US-20050222260-A1 | (2S)-2-amino-a-{[2-(ethanimidoylamino) ethyl]thio}butanoic acid, a nitric oxide synthase inhibitor, in stabilized pharmaceutical dosage forms | SB PHARMCO PUERTO RICO INC. (PR) | 2005-10-06 | — | — | US | claimed |
| EP-1513511-A1 | (2S)-2-AMINO-4- [2-(ETHANIMIDOYLAMINO)ETHYL]THIO BUTANOIC ACID, A NITRIC OXIDE SYNTHASE INHIBITOR, IN STABILIZED PHARMACEUTICAL DOSAGE FORMS | SB Pharmco Puerto Rico Inc. (PR) | 2005-03-16 | — | — | EP | claimed |
| US-20050054726-A1 | Vaccine | GLAXO GROUP LIMITED (GB) | 2005-03-10 | — | — | US | claimed |
| EP-1432440-A2 | ADJUVANTS FOR NUCLEIC ACID VACCINES | GLAXO GROUP LIMITED (GB) | 2004-06-30 | — | — | EP | claimed |
| JP-2004516278-A | — | — | 2004-06-03 | — | — | JP | claimed |
| US-20040087654-A1 | Nitric oxide synthase inhibitor phosphate salt | SMITHKLINE BEECHAM CORPORATION | 2004-05-06 | — | — | US | claimed |
| WO-2004000296-A1 | (2S)-2AMINO-A-{[2-(ETHANIMIDOYLAMINO) ETHYL]THIO}BUTANOIC ACID, A NITRIC OXIDE SYNTHASE INHIBITOR, IN STABILIZED PHARMACEUTICAL DOSAGE FORMS | SB PHARMCO PUERTO RICO INC. (PR) | 2003-12-31 | — | — | WO | claimed |
| EP-1351929-A1 | NITRIC OXIDE SYNTHASE INHIBITOR PHOSPHATE SALT | GLAXO GROUP LIMITED (GB) | 2003-10-15 | — | — | EP | claimed |
| WO-2003030935-A2 | ADJUVANTS FOR NUCLEIC ACID VACCINES | GLAXO GROUP LIMITED (GB) | 2003-04-17 | — | — | WO | claimed |
| WO-2002050021-A1 | NITRIC OXIDE SYNTHASE INHIBITOR PHOSPHATE SALT | GLAXO GROUP LIMITED (GB) | 2002-06-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222260-A1 | (2S)-2-amino-a-{[2-(ethanimidoylamino) ethyl]thio}butanoic acid, a nitric oxide synthase inhibitor, in stabilized pharmaceutical dosage forms | ABAT, ALDH7A1, BBOX1 | NOS2 6/4885BHMT 124/4885BHMT2 55/4885 |
| US-20210009549-A1 | CANNABINOID DERIVATIVES AND CONJUGATES AND USES THEREOF | CNR1, GLRA1, GLRA3 | NOS2 4352/4885BHMT 661/4885BHMT2 1202/4885 |
| US-20050054726-A1 | Vaccine | NOS2, NOS1, NOS3 | NOS2 1/4885BHMT 278/4885BHMT2 376/4885 |
| US-20040087654-A1 | Nitric oxide synthase inhibitor phosphate salt | NOS3, NOS1, SLC20A1 | NOS2 4/4885BHMT 3331/4885BHMT2 3723/4885 |
| US-20250276085-A1 | SYNTHETIC MULTIDOMAIN PEPTIDE BIOMATERIALS THAT INHIBIT INDUCIBLE NITRIC OXIDE SYNTHASE | STING1, CGAS, GMPS | NOS2 7/4885BHMT 190/4885BHMT2 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.